Hard-tech firm Meiyang Innovative Technology has recently declared the successful closure of a Pre-A+ funding round, amassing hundreds of millions of yuan. This round of financing saw the participation of multiple institutions, among which was Guoju Capital, a subsidiary of Guangzhou High-Tech Zone Group. The funds raised from this financing will be predominantly allocated to propel the company's core operations, including registered clinical trials and technological advancements.

Established in 2021, Meiyang Innovative Technology has developed an intelligent closed-loop platform on its own. This platform integrates a range of core technologies and harmonizes various devices. Its Class III medical devices have not only garnered certification from the U.S. Food and Drug Administration (FDA) but have also successfully undergone clinical trials. Additionally, the company has filed for nearly a hundred patents.

In response to international clinical challenges, Meiyang has pioneered innovative technologies, thereby establishing a robust groundwork for clinical translation. Prior to this, the company had already secured two rounds of financing, with Songhe Capital being one of its investors.